Ebolavirus disease causes high mortality, and the current outbreak has spread unabated
through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus …

Background The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an
international response to accelerate the availability of a preventive vaccine. A replication …

Vaccine-induced immunity to Ebola virus infection in nonhuman primates (NHPs) is marked
by potent antigen-specific cellular and humoral immune responses,; however, the immune …

The use of adenoviruses (Ad) as vaccine vectors against a variety of pathogens has
demonstrated their capacity to elicit strong antibody and cell-mediated immune responses …

Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge.
Although an experimental vaccine has successfully protected non-human primates against …

Background The West African outbreak of Ebola virus disease has caused more than 8500
deaths. A vaccine could contribute to outbreak control in the region. We assessed a …

This study evaluated the use of a chimpanzee-based adenovirus vaccine in mouse and
Guinea pigs models of Zaire Ebola virus (ZEBOV) infection. Vaccine vector expressing the …

Ebola viruses are highly pathogenic viruses that cause outbreaks of hemorrhagic fever in
humans and other primates. To meet the need for a vaccine against the several types of …

Background The West African outbreak of Ebola virus disease that peaked in 2014 has
caused more than 11,000 deaths. The development of an effective Ebola vaccine is a priority …

Ebola virus causes irregular outbreaks of severe hemorrhagic fever in equatorial Africa.
Case mortality remains high; there is no effective treatment and outbreaks are sporadic and …